These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 34967572)
1. Polo-Like Kinase 1(PLK1) Immunohistochemical Expression in Triple Negative Breast Carcinoma: A Probable Therapeutic Target. Salama ME; Khairy DA Asian Pac J Cancer Prev; 2021 Dec; 22(12):3921-3925. PubMed ID: 34967572 [TBL] [Abstract][Full Text] [Related]
2. Expression patterns of polo-like kinase 1 in human gastric cancer. Weichert W; Ullrich A; Schmidt M; Gekeler V; Noske A; Niesporek S; Buckendahl AC; Dietel M; Denkert C Cancer Sci; 2006 Apr; 97(4):271-6. PubMed ID: 16630118 [TBL] [Abstract][Full Text] [Related]
3. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Hu K; Law JH; Fotovati A; Dunn SE Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939 [TBL] [Abstract][Full Text] [Related]
4. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Zhang Z; Zhang G; Kong C Urol Oncol; 2013 Oct; 31(7):1222-30. PubMed ID: 22192978 [TBL] [Abstract][Full Text] [Related]
5. CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression. Kong Y; Yang L; Wei W; Lyu N; Zou Y; Gao G; Ou X; Xie X; Tang H Epigenomics; 2019 Aug; 11(10):1163-1176. PubMed ID: 31337246 [No Abstract] [Full Text] [Related]
6. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. Liu J; Lu KH; Liu ZL; Sun M; De W; Wang ZX BMC Cancer; 2012 Nov; 12():519. PubMed ID: 23151088 [TBL] [Abstract][Full Text] [Related]
7. PLK-1 Expression is Associated with Histopathological Response to Neoadjuvant Therapy of Hepatic Metastasis of Colorectal Carcinoma. Fernández-Aceñero MJ; Cortés D; Gómez del Pulgar T; Cebrián A; Estrada L; Martínez-Useros J; Celdrán A; García-Foncillas J; Pastor C Pathol Oncol Res; 2016 Apr; 22(2):377-83. PubMed ID: 26577686 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of PLK1 inhibition in triple-negative breast cancer. Ueda A; Oikawa K; Fujita K; Ishikawa A; Sato E; Ishikawa T; Kuroda M; Kanekura K Lab Invest; 2019 Sep; 99(9):1275-1286. PubMed ID: 30996295 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of polo-like kinase 1 in oral squamous cell carcinoma and oral submucous fibrosis. Vittal K; Pandian SS; Joseph LD; Raj SG Indian J Dent Res; 2018; 29(2):171-175. PubMed ID: 29652009 [TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. Weichert W; Kristiansen G; Schmidt M; Gekeler V; Noske A; Niesporek S; Dietel M; Denkert C World J Gastroenterol; 2005 Sep; 11(36):5644-50. PubMed ID: 16237758 [TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells. Zhang G; Zhang Z; Liu Z Tumour Biol; 2013 Jun; 34(3):1887-94. PubMed ID: 23494182 [TBL] [Abstract][Full Text] [Related]
12. [Expression of checkpoint kinase 1 and polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach]. Yao H; Yang Z; Li Y Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Oct; 35(10):1080-4. PubMed ID: 21051833 [TBL] [Abstract][Full Text] [Related]
13. Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells. Ha GH; Kim DY; Breuer EK; Kim CK Anticancer Res; 2018 Mar; 38(3):1303-1310. PubMed ID: 29491053 [TBL] [Abstract][Full Text] [Related]
14. [Polo like kinase 1 expression and prognostic value in gastric carcinomas]. Lan B; Liu BY; Chen XH; Qu Y; Zhang XQ; Cai Q; Zhu ZG Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Jan; 10(1):70-2. PubMed ID: 17253180 [TBL] [Abstract][Full Text] [Related]
15. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis. Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom. King SI; Purdie CA; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Meek DW Breast Cancer Res; 2012 Mar; 14(2):R40. PubMed ID: 22405092 [TBL] [Abstract][Full Text] [Related]
17. Polo-like kinase 1 expression in medullary carcinoma of the thyroid: its relationship with clinicopathological features. Ito Y; Nakamura Y; Yoshida H; Tomoda C; Uruno T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Kuma K; Kakudo K; Miyauchi A Pathobiology; 2005; 72(4):186-90. PubMed ID: 16127294 [TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Maire V; Némati F; Richardson M; Vincent-Salomon A; Tesson B; Rigaill G; Gravier E; Marty-Prouvost B; De Koning L; Lang G; Gentien D; Dumont A; Barillot E; Marangoni E; Decaudin D; Roman-Roman S; Pierré A; Cruzalegui F; Depil S; Tucker GC; Dubois T Cancer Res; 2013 Jan; 73(2):813-23. PubMed ID: 23144294 [TBL] [Abstract][Full Text] [Related]
19. A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells. Patel JR; Thangavelu P; Terrell RM; Israel B; Sarkar AB; Davidson AM; Zhang K; Khupse R; Tilghman SL Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454120 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis. Ran Z; Chen W; Shang J; Li X; Nie Z; Yang J; Li N Gene; 2019 Dec; 721():144097. PubMed ID: 31493507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]